Integra LifeSciences (NASDAQ:IART) Stock Price Expected to Rise, Citigroup Analyst Says

Integra LifeSciences (NASDAQ:IART) had its price objective lifted by Citigroup from $16.00 to $22.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has a sell rating on the life sciences company’s stock.

A number of other research firms have also recently issued reports on IART. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley lifted their price target on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a report on Monday, July 15th. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. JMP Securities decreased their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Finally, Bank of America dropped their price target on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $27.25.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $25.51 on Tuesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 2.10 and a current ratio of 3.39. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.42. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -283.44, a PEG ratio of 0.82 and a beta of 1.08. The stock has a fifty day moving average price of $18.99 and a 200-day moving average price of $24.41.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.25%. The business’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the prior year, the company posted $0.76 earnings per share. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently modified their holdings of the business. Capital Research Global Investors raised its position in Integra LifeSciences by 37.7% during the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after purchasing an additional 1,621,655 shares during the last quarter. Cooke & Bieler LP increased its stake in shares of Integra LifeSciences by 12.4% in the second quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after buying an additional 388,710 shares during the period. Champlain Investment Partners LLC raised its position in shares of Integra LifeSciences by 10.3% during the first quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock worth $95,289,000 after acquiring an additional 252,015 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after acquiring an additional 12,766 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its holdings in Integra LifeSciences by 64.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after acquiring an additional 335,557 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.